CIC and neoplasm: Restoring CIC repressor activity or silencing of its target genes Etv4 and Etv5 decreases resistance to MAPK pathway inhibition, similar to treatment with drugs (PFK15 and Tx-1123) that selectively affect the viability of Cic-deficient tumor cells.